Abstract: Compounds or salts thereof are described that correspond to general formula (I) below: Also described, are pharmaceutical and cosmetic compositions that include these compounds. Methods of using these compounds and compositions for the treatment of pathological conditions are also described.

Abstract: The present invention describes methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of aging, by topically applying compositions comprising aryl-thiazole compounds.

Abstract: A cleansing agent composition containing (A) a sulfonate-type surfactant and/or a sulfate-type anionic surfactant, and (B) a heterocyclic compound represented by the formula (1) wherein R1 and R2 are each independently a hydrogen atom, a methyl group, a hydroxymethyl group, or a hydroxyethyl group, shows high detergency and low irritativeness, can suppress rough skin after washing and drying, and can be preferably used for cosmetic agents.

Abstract: Suggested is a cosmetic composition, comprising (a) menthone compounds according to formula (Ia) or (Ib) and (b) at least one oil body or wax, and optionally (c) at least one emulsifier and/or (d) at least one active principle.

Abstract: A method is described for producing an oil-in-water emulsion including oil globules, the mean diameter of which is less than 500 nm and each of which is provided with a lamellar liquid crystal coating, and which are dispersed in an aqueous phase. Each oil globule is individually coated with a unilamellar or oligolamellar layer obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant, and at least one separate anionic surfactant, characterized in that the number of steps in the method is no greater than 5, in that the temperatures used during the different steps are no higher than 75° C., and in that the method requires neither the use of a high-pressure homogenizer nor any pre-emulsification step.

Abstract: Provided is a composition containing a sterol ester, which is an oil poorly soluble in water, and superior in transparency, stability, foaming property, rinsability, skin feel (during rinsing and/or after use), and emollience. A composition containing (A) a sterol ester, (B) one or more anionic surfactants selected from (B1) N-acylamino acid having a C8-22 acyl group or a salt thereof, (B2) polyoxyethylene alkyl ether sulfate or a salt thereof, (C) a betaine-type amphoteric surfactant, (D) glyceryl mono-C8-14 fatty acid ester, (E) C5-6 hydroxyalcohol, and (F) water, and having pH 4-8.

Abstract: The invention relates to the field of cosmetology, namely to mineral-enzyme complexes for tooth enamel strengthening and whitening, and also to compositions for oral hygiene comprising said complex, in particular, to toothpastes and other compositions. The described mineral-enzyme complex for tooth enamel strengthening and whitening is characterized by the fact that it contains calcium hydroxyapatite and tannase with the following component proportions: from 0.2 to 10 parts of tannase per 100 mass parts of calcium hydroxyapatite. The said complex may also additionally contain grapeseed extract. Besides, a variety of compositions for oral hygiene are disclosed that comprise the claimed mineral-enzyme complex.

Abstract: Dental adhesive composition comprising (a) a polymerisable monomer or prepolymer, and (b) a solvent comprising t-butanol.

Abstract: The present invention provides a gel polish composition characterized by containing no irritating reactive (meth)acrylate monomer, such as hydroxyethylmethacrylate (HEMA) and ethyl methacrylate (EMA). In the present invention, the gel polish composition comprises at least an aliphatic urethane acrylate oligomer, a polyester acrylate oligomer, a low-irritating acrylate monomer, and a photoinitiator. The gel polish composition possesses low or no irritating effects to skin, exhibits excellent adhesiveness to nails, and is stable in long-term storage at ordinary shelf conditions.

Abstract: Cosmetic compositions are provided, which are capable of forming an immiscible multi-layered composition. Cosmetic compositions according to the invention typically include a first composition comprised of a pH dependent film-forming polymer with a target pH and wherein the pH of the first composition is greater than the target pH, and a second composition having a pH less than or equal to the target pH. The immiscible multi-layered composition enable various optical effects that provide enhance coverage, color trueness and enhanced naturalness.

Abstract: A hair cosmetic composition comprising the following components (A) to (C): (A) A polymer or copolymer having the structural units represented by the general formula (1): (B) cyclodextrin; and (C) 50 to 95% by mass of water.

Abstract: Disclosed is a shampoo composition comprising a silicone component which comprises a dimethiconol, a blend of dimethicone with surface active block copolymer, and further comprises an aminosilicone. The shampoo can provide improved conditioning benefit.

Abstract: The present invention relates to organosilicon polymers containing benzoic acid esters in form of particles, process for their preparation, cosmetic or dermatological composition comprising them, as well as their use for protecting a human or animal living body from UV radiation.

Abstract: The present invention provides a novel substance that promotes expression of filaggrin gene involved in improvement of the moisture retention function of skin. The inventors of the present invention found that expression of filaggrin gene fluctuates rhythmically over a roughly 24 hour cycle, screened candidate substances based on the time at which expression reaches a maximum following addition of the candidate substance, and identified zanthoxylum extract, 3-(1?-piperidine)propionic acid, geranium oil, cypress oil, rose oil, galvanum oil, pepper oil, basil oil, methyl-o-toluate, methyl anthranilate and dimethyl anthranilate as filaggrin gene expression promoting agents.

Abstract: The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus Stelitzia. When topically applied to skin, the composition is effective in accelerating the degradation of heme by-products such as bilirubin present in the skin.

Abstract: Disclosed is a method of lightening skin or evening skin tone, the method comprising topically applying to skin in need thereof a composition comprising an extract from Rhododendron moulmainense, wherein topical application of the composition lightens skin or evens skin tone.

Abstract: Methods of using WIPI-1 to impart anti-aging benefits to the skin and/or improve skin conditions resulting from reduced autophagy activity.

Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.

Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. Additionally or optionally, there is a step of applying a sufficient amount of a liquid to the treatment area after substantial evaporation of the formulation leaves a particle residue on the skin surface. Thereafter, one or more steps of facilitating delivery of particles into a portion of the skin are repeated. Finally, the particles are exposed to a suitable energy activation, thereby providing the desired treatment or clinical outcome.

Abstract: The present invention relates to a material in the form of solid particles with a diameter varying from 1 ?m to 1 cm which are composed of a continuous shell EExt comprising at least one silicon oxide, said shell EExt imprisoning at least one fatty phase, said material being characterized in that said fatty phase is solid at the storage temperature of said material and predominantly comprises a crystallizable oil having a melting point (TM) of less than 100° C. and in that said fatty phase includes at least one lipophilic substance of interest SL and at least one inclusion comprising a continuous shell EInt comprising at least one silicon oxide, said shell EInt imprisoning an aqueous phase comprising at least one hydrophilic substance of interest SH. The invention also relates to a process for the preparation of said material, to its use for the thermostimulated delivery of active substances, and also to the compositions including it.

Abstract: The present invention relates to a lyophilizate comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. The present invention also relates to a composition comprising: a solution comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. Finally, the present invention relates to a process for preparing the lyophilizate.

Abstract: Oral insulin formulations and processes for preparing oral insulin formulations are provided.

Abstract: Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90% release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer.

Abstract: This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.

Abstract: A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.

Abstract: A pharmaceutical or nutraceutical composition with a core, an inner coating layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, one or more salts of alginic acid is contained in the inner coating layer, and one or more water-insoluble polymers or copolymers is contained in the outer coating layer. In the composition, the ratio of the amount of the one or more salts of alginic acid in the inner coating layer is at least 2.5:1 by weight to the amount of the one or more water-insoluble polymers or copolymers in the outer coating layer.

Abstract: Multilayer, active substance-containing transdermal therapeutic system (TTS) for releasing active substances via the skin to the human body. A disadvantage of known transdermal therapeutic systems is that, due to insufficient cohesion, they are prone to smear during application on the skin and therefore do not reliably adhere to the skin. To improve cohesion, a TTS (10) comprises two or more self-adhesive adhesive layers (1, 3, 3?, 3?) and at least one non-self-adhesive, high-tensile-strength and active substance-permeable intermediate layer (2, 2?, 2?); the said adhesive layers and intermediate layer(s) are alternately arranged and joined to one another. The multilayer TTS is suited for the administration of pharmaceutical active substances via the skin for therapeutic purposes.

Abstract: The invention relates to a monopolymer multifunctional sequenced cast polyurethane matrix produced simply and efficiently, by sequentially pouring various isocyanate/polyol complex phase solutions successively into a mould with alternating solidification of said phase solutions according to a defined order and respecting the polymerisation stage (after the pot life and before the demoulding time) of the sequence preceding the one being cast, so as to end with the casting of the last phase solution that will go up to the demoulding time thereof and thereby finish the polymerisation of the whole of the matrix. It is loaded, in its “reservoir” sequences, with naturally originating or synthesised transdermally penetrating or volatile active substances. They are medicating and therapeutic, cosmetic, phytosanitary or wellness substances, repellents, attractants, pheromones, biocides, perfumes or deodorants.

Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.

Abstract: The present invention relates to a method for suppressing the libido in livestock and increasing the meat production, wherein fluoxetine or a pharmaceutically acceptable salt, solvate, polymorph, or a racemic mixture thereof is administered to the livestock.

Abstract: Urinary incontinence is treated by administration of pharmaceutical compositions containing at least one nitrone spin trap such as ?-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and methods of treatment further include at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and polyenylphosphatidylcholine.

Abstract: Urinary incontinence is treated by administration of pharmaceutical compositions containing at least one nitrone spin trap such as ?-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and methods of treatment further include at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and polyenylphosphatidylcholine.

Abstract: A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition comprising or consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition to below 4.6. Topical administration of the composition is preferred and is effective in treating lesions associated infections by viruses such as Herpes simplex. Nasal deliverable forms are effective in treating symptoms due to viruses that cause the common cold. Pharmaceutical compositions for use in the present method are provided.

Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).

Abstract: The use of an emulsion for protecting the skin against aggressive chemical agents, wherein this emulsion includes at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y) Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c?being a relative number having the same absolute value as c.

Abstract: This invention is related to the obtainment of a new active ingredient and its obtaining process from green or ripe fruits of both Acrocomia crispa and Acrocomia aculeata species of the Arecaceae family. Such active ingredient can be used as nutritional supplement, cosmetic-therapeutic formulations, or as pharmaceutical compositions for preventing and/or treating inflammatory processes and oxidative stress, and includes a mixture of fatty acids from 6 to 28 carbon atoms (free and/or as acylglycerols or ethyl esters), mainly those saturated of linear chain with 8, 10, 12, 14, 16 and 18 carbon atoms, and those unsaturated of 16 and 18 carbon atoms, and that may also contain sterols and fatty alcohols.

Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Abstract: Methods of therapeutic treatment using monomethyl fumarate are disclosed.

Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is convalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.

Abstract: The present invention is based on the discovery that motor neurons derived from patients with a neuro-degenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neurons derived from control healthy individuals. The present invention is also based on the discovery that the class of compounds known as “potassium channel openers” can be used to treat neurodegenerative diseases, including ALS, Parkinson's disease, Alzheimer's disease, epilepsy, and pain.

Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Abstract: The present invention relates generally to methods for inhibiting neuron apoptosis and necrosis associated with excess glutamate release.

Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.

Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: There is described herein a use of quercetin-3-O-?-D-glucoside (Q3G) for increasing the amount of cell surface low-density lipoprotein receptor (LDLR) on a cell and for reducing the amount of functional proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by the cell, where the Q3G is formulated for administration to the cell, and where the increase in cell surface LDLR and the decrease in secretion of functional PCSK9 is in comparison to the cell not exposed to Q3G. The use may optionally include the treatment of a statin. There is also described a method of reducing plasma cholesterol levels in a patient in need thereof. The method includes treating the patient with a therapeutically effective amount of Q3G and, optionally, a therapeutically effective amount of a statin.

Abstract: The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.

Abstract: A composition in the form of a gel, preferably hydroglycolic, is described. The composition can include in a physiologically acceptable medium, at least one particular retinoid. Also described, is a method for the preparation thereof and the cosmetic and dermatological use of the same.

Abstract: Microcapsules are described that include a pharmaceutical active agent selected from among retinoids, an anionic hydrophilic polymer (in particular, gum arabic), and a cationic hydrophilic polymer (in particular, type-A gelatin). Also described, are methods for preparing such microcapsules, topical pharmaceutical compositions including such microcapsules, and dermatological uses thereof.